ClinicalTrials.gg
CompletedNCT00638690Updated Apr 30, 2014Results posted

Abiraterone Acetate in Castration-Resistant Prostate Cancer Previously Treated With Docetaxel-Based Chemotherapy

A Phase 3 interventional study of Placebo and Abiraterone acetate in Prostatic Neoplasms, sponsored by Cougar Biotechnology, Inc.. Completed at 128 sites in 12 countries. Open to male participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2014-04-30.

Sponsored by Cougar Biotechnology, Inc. (part of Johnson & Johnson) · Phase 3, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 3
Study type
Interventional
Enrollment
1,195
Allocation
Randomized
Ages
18 Years and older
Sex
Male
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 98 studies testing Abiraterone Acetate in Prostatic Neoplasms — 12 open to participants now, 29 under way, 4 of them phase 3. Abiraterone Acetate · Prostatic Neoplasms.

Enrollment
3rd of 98
1,195 · median 56
Started
2008
the only one that year
Phase 3
11 of 98
2 open now
Registered
7th of 98
by date
Lead sponsor
6 of 98
Cougar Biotechnology, Inc.

Among the 98 studies testing Abiraterone Acetate in Prostatic Neoplasms, this one is the 3rd largest by enrollment, is the only one that started in 2008, is one of 11 in phase 3, and was the 7th registered.

Prostatic Neoplasms

7,051 studies on the registry are indexed under Prostatic Neoplasms; 1,582 are open to participants now.

Browse Prostatic Neoplasms studies →

Open to participants now

12 of the 98 studies testing Abiraterone Acetate in Prostatic Neoplasms are open now, in 8 countries. Recruiting first, the newest first:

7 more — sign in →

By country, each count listing its studies:

All 12 open studies →

About Abiraterone Acetate

Abiraterone Acetate: first FDA approval 2011 (ZYTIGA), first EMA approval 2011. What it is approved for, and how studies give it, is on its page →

Who these studies take

Of the 1,230 Prostatic Neoplasms studies recruiting now, 929 (76%) set no upper age limit and 76 (6%) stop at 75 or younger; 67 take children under 18; 82 take healthy volunteers.

This study: 18 Years and older · male · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 98 studies testing Abiraterone Acetate in Prostatic Neoplasms, or all of them as a file.
02

Study summary

This is a phase 3 study to compare the clinical benefit of abiraterone acetate plus prednisone with placebo plus prednisone in patients with metastatic castration-resistant prostate cancer (CRPC) who have failed one or two chemotherapy regimens. At least one of the previous chemotherapies must have contained docetaxel.

Read the detailed description

Abiraterone acetate is a steroidal irreversible inhibitor of CYP17 (17α hydroxylase/C17, 20-lyase), blocking 2 important enzymatic activities in the synthesis of testosterone. The goal of this study is to compare the clinical benefit of abiraterone acetate plus prednisone with placebo plus prednisone in patients with metastatic castration-resistant prostate cancer (CRPC) who have failed one or two chemotherapy regimens, one of which contains docetaxel. All patients involved in the study will be randomized (assigned by chance) into one of two arms and will not know what study drug is being given to them. Study drug randomization allocation will be 2:1 (abiraterone acetate: placebo). The study will be conducted in the United States, Canada, Australia, and the EU. The study will consist of screening, treatment, and follow-up. In this study, patients will receive study treatment (abiraterone acetate or placebo) plus prednisone until progression of clinical disease. Follow-up will continue until patient dies, is lost to follow-up, or withdraws informed consent. After providing written informed consent, patients will have screening procedures completed to determine eligibility. Safety evaluations at the screening procedure will include a physical examination, vital signs, and clinical blood laboratory tests, ECG, radiographs, urine tests, and recording of any adverse events including details of current prostate cancer symptoms. Patients will be asked to use a method of birth control with adequate barrier protection as determined to be acceptable by the principal investigator and sponsor during the study and for 13 weeks after last study drug administration.

Study medication, abiraterone acetate,is an oral (by mouth) medication to be administered as four (4) 250mg abiraterone acetate tablets or 4 placebo tablets to be taken at least one hour before or two hours after a meal anytime up to 10PM everyday. Prednisone will be administered as 5mg orally twice a day for both groups. Each cycle will be 28 days. Study treatment will continue until disease progression as determined by investigator or when the patient meets criteria for withdrawal from study.

03

Conditions studied

  • Prostatic Neoplasms

Browse trials for

Keywords

  • Metastatic Castration-Resistant Prostate Cancer
  • CRPC
  • Abiraterone Acetate
  • CB7630
04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
Male
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Castration-Resistant Prostate Cancer Progression after one or two prior cytotoxic chemotherapies
  • At least one chemotherapy must have contained docetaxel
  • (ECOG) Performance Status \<= 2
  • Medical or surgical castration with testosterone \< 50 ng/dL
  • Adequate bone marrow, hepatic and renal function
  • Potassium >= 3.5 mmol/L
  • Able to swallow the study drug whole as a tablet

Exclusion criteria

Exclusion Criteria:

  • More than two prior cytotoxic chemotherapy regimens
  • Prior Ketoconazole for prostate cancer
  • Prior abiraterone acetate or other CYP17 inhibitor or agents targeting the androgen receptor for prostate cancer
  • Uncontrolled hypertension
  • Active or symptomatic viral hepatitis or chronic liver disease
  • History of pituitary or adrenal dysfunction
  • heart disease
  • Other
  • Known
  • GI disorder affecting absorption
  • Not willing to use
Terms in these criteria, in plain language(8)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Metastases

Cancer that has spread from where it began to other parts of the body. “Metastatic” cancer is cancer that has spread this way.

ECOG performance status

A scale of how much an illness limits everyday activity. For people being assessed to join a study, scores run from 0 (fully active) to 4; lower is more active.

0
Fully active, no restrictions.
1
Limited in strenuous activity, but walking and able to do light work, such as housework or office work.
2
Walking and able to look after yourself, but unable to work; up and about more than half of waking hours.
3
Able to look after yourself only in part; in bed or a chair more than half of waking hours.
4
Unable to look after yourself at all; in bed or a chair all day.

Studies most often ask for 0–1 or 0–2. Your doctor gives the score; the WHO scale uses the same steps. The full scale also has 5, which records death.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

Cancer (malignancy)

Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.

Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.

Brain metastases

Cancer deposits in the brain from a cancer that started elsewhere in the body (CNS metastases include the spinal cord).

Studies differ: some leave out any brain metastases, some accept ones treated and stable for some weeks. Check what this study allows.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

05

Study design

Phase
Phase 3
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Quadruple (Participant, Care provider, Investigator, Outcomes assessor)
Enrollment
1,195 participants (actual)

Study arms

  • Experimental
    Abiraterone acetate plus prednisone/prednisolone

    Drug: Abiraterone acetate · Drug: Prednisone/prednisolone

  • Placebo comparator
    Placebo plus prednisone/prednisolone

    Drug: Placebo · Drug: Prednisone/prednisolone

Interventions

  • DrugPlacebo

    Four tablets once daily until disease progression

  • Four 250-mg tablets once daily until disease progression

  • DrugPrednisone/prednisolone

    Drug pages: Prednisone · Prednisolone

    5 mg twice daily until disease progression

06

What researchers measure

Primary outcomes

  1. Overall Survival

    Overall survival is defined as the time interval from the date of randomization to the date of death from any cause.

    Time frame: Up to 60 months

Secondary outcomes

  1. Time to Prostate-Specific Antigen Progression According to Prostate Specific Antigen Working Group Criteria

    The time interval from the date of randomization to the date of the prostate-specific antigen (PSA) progression as defined in the protocol-specific Prostate Specific Antigen Working Group (PSAWG) criteria, namely, a PSA level of at least 5 ng/ml that has risen on at least 2 successive occasions, at least 2 weeks apart.

    Time frame: Up to 12 months

  2. Number of Patients Achieving a Prostate-Specific Antigen Decline >=50%

    A prostate-specific antigen (PSA) response was defined as a \>=50% decline from baseline.

    Time frame: Up to 12 months

  3. Radiographic Progression-free Survival

    Radiographic progression-free survival is based on imaging studies according to modified Response Evaluation Criteria in Solid Tumors (RECIST): baseline lymph node size must be \>=2.0 cm to be considered a target lesion; progression on bone scans with \>=2 new lesions not consistent with tumor flare, confirmed on a second scan \>=6 weeks later that shows \>=1 additional new lesion.

    Time frame: Up to 11 months

07

Results

Posted May 16, 2013

Participant flow

Participant flow — Overall Study
MilestoneAbiraterone AcetatePlacebo
Started797398
Completed11656
Not completed681342
Withdrew: Death655335
Withdrew: Withdrawal by subject225
Withdrew: Lost to follow-up42

Outcome measures

PrimaryOverall Survival

Overall survival is defined as the time interval from the date of randomization to the date of death from any cause.

Time frame:
Up to 60 months
Reported as:
Median · Days
Overall Survival
DaysAbiraterone AcetatePlacebo
Overall Survival450.0 (430.0 to 470.0)332.0 (310.0 to 366.0)
Statistical analysis
  • Abiraterone Acetate vs Placebo · Log Rank · p = <0.0001 (Nominal P-value is 0.0142 at interim analysis based on group sequential design.) · Hazard ratio (hr): 0.646 · 95% CI 0.543 to 0.768This was a stratified analysis.
SecondaryTime to Prostate-Specific Antigen Progression According to Prostate Specific Antigen Working Group Criteria

The time interval from the date of randomization to the date of the prostate-specific antigen (PSA) progression as defined in the protocol-specific Prostate Specific Antigen Working Group (PSAWG) criteria, namely, a PSA level of at least 5 ng/ml that has risen on at least 2 successive occasions, at least 2 weeks apart.

Time frame:
Up to 12 months
Reported as:
Median · Days
Time to Prostate-Specific Antigen Progression According to Prostate Specific Antigen Working Group Criteria
DaysAbiraterone AcetatePlacebo
Time to Prostate-Specific Antigen Progression According to Prostate Specific Antigen Working Group Criteria309.0 (255.0 to 421.0)200.0 (170.0 to 254.0)
Statistical analysis
  • Abiraterone Acetate vs Placebo · Log Rank · p = <0.0001 (Nominal P-value = 0.05.) · Hazard ratio (hr): 0.580 · 95% CI 0.462 to 0.728This was a stratified analysis.
SecondaryNumber of Patients Achieving a Prostate-Specific Antigen Decline >=50%

A prostate-specific antigen (PSA) response was defined as a \>=50% decline from baseline.

Time frame:
Up to 12 months
Reported as:
Number · Participants
Number of Patients Achieving a Prostate-Specific Antigen Decline >=50%
ParticipantsAbiraterone AcetatePlacebo
Number of Patients Achieving a Prostate-Specific Antigen Decline >=50%23222
Statistical analysis
  • Abiraterone Acetate vs Placebo · Chi-squared · p = <0.001 (Nominal P-value = 0.05.) · Risk ratio (rr): 5.266 · 95% CI 3.459 to 8.018
SecondaryRadiographic Progression-free Survival

Radiographic progression-free survival is based on imaging studies according to modified Response Evaluation Criteria in Solid Tumors (RECIST): baseline lymph node size must be \>=2.0 cm to be considered a target lesion; progression on bone scans with \>=2 new lesions not consistent with tumor flare, confirmed on a second scan \>=6 weeks later that shows \>=1 additional new lesion.

Time frame:
Up to 11 months
Reported as:
Median · Days
Radiographic Progression-free Survival
DaysAbiraterone AcetatePlacebo
Radiographic Progression-free Survival171.0 (169.0 to 192.0)110.0 (88.0 to 168.0)
Statistical analysis
  • Abiraterone Acetate vs Placebo · Log Rank · p = <0.0001 (The nominal P-value = 0.05.) · Hazard ratio (hr): 0.673 · 95% CI 0.585 to 0.776This was a stratified analysis.

Adverse events

Collected over 5 years. Non-serious events are listed at a 5% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
Abiraterone Acetate—365/791 (46.1%)766/791 (96.8%)
Placebo—175/394 (44.4%)381/394 (96.7%)
Placebo to Abiraterone Acetate—29/67 (43.3%)57/67 (85.1%)
Most frequent serious events
Showing 10 of 328
Most frequent serious events
EventAbiraterone AcetatePlaceboPlacebo to Abiraterone Acetate
Back painMusculoskeletal and connective tissue disorders12/79111/3944/67
Spinal cord compressionNervous system disorders23/79118/3943/67
PyrexiaGeneral disorders6/7919/3943/67
PneumoniaInfections and infestations21/7915/3943/67
Urinary tract infectionInfections and infestations19/7913/3943/67
AnaemiaBlood and lymphatic system disorders26/79115/3941/67
Bone painMusculoskeletal and connective tissue disorders16/79113/3941/67
OsteonecrosisMusculoskeletal and connective tissue disorders2/7910/3942/67
HydronephrosisRenal and urinary disorders12/7913/3942/67
Disease progressionGeneral disorders12/7912/3942/67
Most frequent other events
Showing 10 of 53
Most frequent other events
EventAbiraterone AcetatePlaceboPlacebo to Abiraterone Acetate
FatigueGeneral disorders384/791172/39419/67
Back painMusculoskeletal and connective tissue disorders282/791138/39423/67
NauseaGastrointestinal disorders272/791132/39419/67
ConstipationGastrointestinal disorders236/791124/39414/67
ArthralgiaMusculoskeletal and connective tissue disorders246/79193/39420/67
Oedema peripheralGeneral disorders228/79175/39411/67
Bone painMusculoskeletal and connective tissue disorders219/791112/39412/67
AnaemiaBlood and lymphatic system disorders202/791105/39411/67
VomitingGastrointestinal disorders204/79197/39414/67
Pain in extremityMusculoskeletal and connective tissue disorders170/79181/39413/67

Baseline characteristics

Age, Continuous
Age, Continuous(years)Abiraterone AcetatePlaceboTotal
Mean69.1 ± 8.468.9 ± 8.6169 ± 8.46
Sex: Female, Male
Sex: Female, Male(Participants)Abiraterone AcetatePlaceboTotal
Female000
Male7973981195
Region of Enrollment
Region of Enrollment(participants)Abiraterone AcetatePlaceboTotal
Australia6935104
Austria11112
Belgium321143
Canada9757154
France573390
Germany261238
Hungary527
Italy211233
Netherlands426
Republic of Ireland7714
Spain13316
United Kingdom11961180
United States336162498
08

Study locations

128 sites
  • Birmingham, Alabama, United States
  • Tucson, Arizona, United States
  • Beverly Hills, California, United States
  • Duarte, California, United States
  • Los Angeles, California, United States
  • Marina Del Rey, California, United States
  • Sacramento, California, United States
  • San Diego, California, United States
  • San Francisco, California, United States
  • Aurora, Colorado, United States
  • Bristol, Connecticut, United States
  • New Haven, Connecticut, United States
  • Stamford, Connecticut, United States
  • Boca Raton, Florida, United States
  • Fort Lauderdale, Florida, United States
  • Fort Myers, Florida, United States
  • West Palm Beach, Florida, United States
  • Atlanta, Georgia, United States
  • Honolulu, Hawaii, United States
  • Chicago, Illinois, United States
  • Galesburg, Illinois, United States
  • Indianapolis, Indiana, United States
  • Westwood, Kansas, United States
  • Wichita, Kansas, United States
  • Marrero, Louisiana, United States
  • New Orleans, Louisiana, United States
  • Baltimore, Maryland, United States
  • Boston, Massachusetts, United States
  • Detroit, Michigan, United States
  • Robbinsdale, Minnesota, United States
  • St. Louis, Missouri, United States
  • Billings, Montana, United States
  • Omaha, Nebraska, United States
  • Las Vegas, Nevada, United States
  • Box 302, New York, United States
  • East Setauket, New York, United States
  • New Hyde Park, New York, United States
  • New York, New York, United States
  • Stony Brook, New York, United States
  • Durham, North Carolina, United States
  • Raleigh, North Carolina, United States
  • Canton, Ohio, United States
  • Cincinnati, Ohio, United States
  • Portland, Oregon, United States
  • Philadelphia, Pennsylvania, United States
  • Pittsburgh, Pennsylvania, United States
  • Myrtle Beach, South Carolina, United States
  • Chattanooga, Tennessee, United States
  • Nashville, Tennessee, United States
  • Dallas, Texas, United States
  • Houston, Texas, United States
  • San Antonio, Texas, United States
  • Virgiania Beach, Virginia, United States
  • Seattle, Washington, United States
  • Adelaide, Australia
  • Camperdown, Australia
  • Footscray, Australia
  • Geelong, Australia
  • Heidelberg, Australia
  • Herston, Australia
  • Hobart, Australia
  • Hornsby, Australia
  • Kogarah, Australia
  • Kurralta Park, Australia
  • Liverpool, Australia
  • Milton, Australia
  • Parkville, Australia
  • Perth, Australia
  • Subiaco, Australia
  • Wodonga, Australia
  • Wollongong, Australia
  • Linz, Austria
  • Salzburg, Austria
  • Wien, Austria
  • Antwerpen, Belgium
  • Bonheiden, Belgium
  • Bruxelles, Belgium
  • Gent, Belgium
  • Hasselt, Belgium
  • Kortrijk, Belgium
  • Leuven, Belgium
  • Liege, Belgium
  • Roeselare, Belgium
  • Edmonton, Alberta, Canada
  • Kelowna, British Columbia, Canada
  • Vancouver, British Columbia, Canada
  • Victoria, British Columbia, Canada
  • Halifax, Nova Scotia, Canada
  • Hamilton, Ontario, Canada
  • Toronto, Ontario, Canada
  • Montreal, Quebec, Canada
  • Regina, Saskatchewan, Canada
  • Calgary Ab, Canada
  • London, Canada
  • Angers Cedex 01, France
  • Caen, France
  • Cannes, France
  • Dijon, France
  • Lyon, France
  • Paris, France

Showing the first 100 of 128 sites across 12 countries. Choose a country and city above to see the rest.

09

References and documents

Publications

  • Heller G, McCormack R, Kheoh T, Molina A, Smith MR, Dreicer R, Saad F, de Wit R, Aftab DT, Hirmand M, Limon A, Fizazi K, Fleisher M, de Bono JS, Scher HI. Circulating Tumor Cell Number as a Response Measure of Prolonged Survival for Metastatic Castration-Resistant Prostate Cancer: A Comparison With Prostate-Specific Antigen Across Five Randomized Phase III Clinical Trials. J Clin Oncol. 2018 Feb 20;36(6):572-580. doi: 10.1200/JCO.2017.75.2998. Epub 2017 Dec 22. PubMed 29272162 ↗
  • Chi KN, Kheoh T, Ryan CJ, Molina A, Bellmunt J, Vogelzang NJ, Rathkopf DE, Fizazi K, Kantoff PW, Li J, Azad AA, Eigl BJ, Heng DY, Joshua AM, de Bono JS, Scher HI. A prognostic index model for predicting overall survival in patients with metastatic castration-resistant prostate cancer treated with abiraterone acetate after docetaxel. Ann Oncol. 2016 Mar;27(3):454-60. doi: 10.1093/annonc/mdv594. Epub 2015 Dec 18. PubMed 26685010 ↗
  • Fizazi K, Flaig TW, Stockle M, Scher HI, de Bono JS, Rathkopf DE, Ryan CJ, Kheoh T, Li J, Todd MB, Griffin TW, Molina A, Ohlmann CH. Does Gleason score at initial diagnosis predict efficacy of abiraterone acetate therapy in patients with metastatic castration-resistant prostate cancer? An analysis of abiraterone acetate phase III trials. Ann Oncol. 2016 Apr;27(4):699-705. doi: 10.1093/annonc/mdv545. Epub 2015 Nov 25. PubMed 26609008 ↗
  • Antoun S, Bayar A, Ileana E, Laplanche A, Fizazi K, di Palma M, Escudier B, Albiges L, Massard C, Loriot Y. High subcutaneous adipose tissue predicts the prognosis in metastatic castration-resistant prostate cancer patients in post chemotherapy setting. Eur J Cancer. 2015 Nov;51(17):2570-7. doi: 10.1016/j.ejca.2015.07.042. Epub 2015 Aug 13. PubMed 26278649 ↗
  • Xu XS, Ryan CJ, Stuyckens K, Smith MR, Saad F, Griffin TW, Park YC, Yu MK, Vermeulen A, Poggesi I, Nandy P. Correlation between Prostate-Specific Antigen Kinetics and Overall Survival in Abiraterone Acetate-Treated Castration-Resistant Prostate Cancer Patients. Clin Cancer Res. 2015 Jul 15;21(14):3170-7. doi: 10.1158/1078-0432.CCR-14-1549. Epub 2015 Mar 31. PubMed 25829400 ↗
  • Scher HI, Heller G, Molina A, Attard G, Danila DC, Jia X, Peng W, Sandhu SK, Olmos D, Riisnaes R, McCormack R, Burzykowski T, Kheoh T, Fleisher M, Buyse M, de Bono JS. Circulating tumor cell biomarker panel as an individual-level surrogate for survival in metastatic castration-resistant prostate cancer. J Clin Oncol. 2015 Apr 20;33(12):1348-55. doi: 10.1200/JCO.2014.55.3487. Epub 2015 Mar 23. PubMed 25800753 ↗
  • Mulders PF, Molina A, Marberger M, Saad F, Higano CS, Chi KN, Li J, Kheoh T, Haqq CM, Fizazi K. Efficacy and safety of abiraterone acetate in an elderly patient subgroup (aged 75 and older) with metastatic castration-resistant prostate cancer after docetaxel-based chemotherapy. Eur Urol. 2014 May;65(5):875-83. doi: 10.1016/j.eururo.2013.09.005. Epub 2013 Sep 20. PubMed 24099659 ↗
  • Harland S, Staffurth J, Molina A, Hao Y, Gagnon DD, Sternberg CN, Cella D, Fizazi K, Logothetis CJ, Kheoh T, Haqq CM, de Bono JS, Scher HI; COU-AA-301 Investigators. Effect of abiraterone acetate treatment on the quality of life of patients with metastatic castration-resistant prostate cancer after failure of docetaxel chemotherapy. Eur J Cancer. 2013 Nov;49(17):3648-57. doi: 10.1016/j.ejca.2013.07.144. Epub 2013 Aug 22. PubMed 23973186 ↗
  • Ryan CJ, Molina A, Li J, Kheoh T, Small EJ, Haqq CM, Grant RP, de Bono JS, Scher HI. Serum androgens as prognostic biomarkers in castration-resistant prostate cancer: results from an analysis of a randomized phase III trial. J Clin Oncol. 2013 Aug 1;31(22):2791-8. doi: 10.1200/JCO.2012.45.4595. Epub 2013 Jul 1. PubMed 23816964 ↗
  • Logothetis CJ, Basch E, Molina A, Fizazi K, North SA, Chi KN, Jones RJ, Goodman OB, Mainwaring PN, Sternberg CN, Efstathiou E, Gagnon DD, Rothman M, Hao Y, Liu CS, Kheoh TS, Haqq CM, Scher HI, de Bono JS. Effect of abiraterone acetate and prednisone compared with placebo and prednisone on pain control and skeletal-related events in patients with metastatic castration-resistant prostate cancer: exploratory analysis of data from the COU-AA-301 randomised trial. Lancet Oncol. 2012 Dec;13(12):1210-7. doi: 10.1016/S1470-2045(12)70473-4. Epub 2012 Nov 9. PubMed 23142059 ↗
  • Fizazi K, Scher HI, Molina A, Logothetis CJ, Chi KN, Jones RJ, Staffurth JN, North S, Vogelzang NJ, Saad F, Mainwaring P, Harland S, Goodman OB Jr, Sternberg CN, Li JH, Kheoh T, Haqq CM, de Bono JS; COU-AA-301 Investigators. Abiraterone acetate for treatment of metastatic castration-resistant prostate cancer: final overall survival analysis of the COU-AA-301 randomised, double-blind, placebo-controlled phase 3 study. Lancet Oncol. 2012 Oct;13(10):983-92. doi: 10.1016/S1470-2045(12)70379-0. Epub 2012 Sep 18. Erratum In: Lancet Oncol. 2012 Nov;13(11):e464. Lancet Oncol. 2014 Aug;15(9):e365. PubMed 22995653 ↗
  • de Bono JS, Logothetis CJ, Molina A, Fizazi K, North S, Chu L, Chi KN, Jones RJ, Goodman OB Jr, Saad F, Staffurth JN, Mainwaring P, Harland S, Flaig TW, Hutson TE, Cheng T, Patterson H, Hainsworth JD, Ryan CJ, Sternberg CN, Ellard SL, Flechon A, Saleh M, Scholz M, Efstathiou E, Zivi A, Bianchini D, Loriot Y, Chieffo N, Kheoh T, Haqq CM, Scher HI; COU-AA-301 Investigators. Abiraterone and increased survival in metastatic prostate cancer. N Engl J Med. 2011 May 26;364(21):1995-2005. doi: 10.1056/NEJMoa1014618. PubMed 21612468 ↗
10

Timeline

Tracking since Sep 25, 2026
Not marked actual or estimatedDates not marked actual or estimated

The record gives a start of May 2008, a primary completion of Aug 2010 and a completion of Oct 2012. It does not say whether these dates are actual or estimated.

Results were first posted in May 2013, 2 years 9 months after primary completion.

How these figures are worked out, and which studies are left out of them.

Registered
Mar 13, 2008
First posted
Mar 19, 2008
Start
May 2008
Primary completionActual
Aug 2010
CompletionActual
Oct 2012
Results first posted
May 16, 2013
Last update
Apr 30, 2014
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Apr 30, 2014, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
11

Registry details

Key details

Study ID
NCT00638690
Responsible party
Sponsor
First posted
Mar 19, 2008
Start date
May 2008
Primary completion
Aug 2010
Completion
Oct 2012
Results posted
May 16, 2013
Last update
Apr 30, 2014

Study contacts

Cougar Biotechnology, Inc Clinical Trial
study director · Cougar Biotechnology, Inc.

Oversight

Data monitoring committee
Yes
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Apr 2014. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Abiraterone Acetate

Start the discussion